(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 February 2008 (21.02.2008)

PCT

(10) International Publication Number
WO 2008/021729 A3

(51) **International Patent Classification:**
A61K 31/343 **(2006.01)** ***A61K 31/4725*** **(2006.01)**
A61K 31/404 **(2006.01)** ***A61K 31/395*** **(2006.01)**
A61K 31/4184 **(2006.01)** ***A61K 45/06*** (2006.01)
A61K 31/4439 **(2006.01)** *A61P 27/00* (2006.01)
A61K 31/4709 **(2006.01)**

(21) **International Application Number:**
PCT/US2007/074943

(22) International Filing Date: 1 August 2007 (01.08.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/836,078 7 August 2006 (07.08.2006) US

(71) **Applicant** *(for all designated States except US):* **BAUSCH & LOMB INCORPORATED** [US/US]; One Bausch & Lomb Place, Rochester, NY 14604-2701 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only):* **KERPPOLA, Raili** [US/US]; 820 Heatherway, Ann Arbor, MI 48104 (US). **PHILLIPS, Gary** [US/US]; 137 Tennyson Way, Pittsford, NY 14534 (US). **HU, Zhenze** [US/US]; 35 Broadmoor Trail, Fairport, NY 14450 (US). **WARD, Keith, Wayne** [US/US]; 5340 Lincoln Road, Ontario, NY 14519 (US).

(74) Agents: POWERS, Jeffrey, B. et al; Bausch & Lomb Incorporated, One Bausch & Lomb Place, Rochester, NY 14604-2701 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available):* AE, AG, AL, AM, AT, AU, **AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC,** EE, **EG,** ES, **FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID,** IL, IN, IS, **JP, KE, KG, KM, KN, KP, KR, KZ,** LA, **LC, LK,** LR, LS, LT, LU, **LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ,** NA, **NG,** NI, NO, **NZ, OM, PG, PH, PL, PT,** RO, RS, RU, **SC, SD,** SE, **SG, SK,** SL, **SM, SV, SY, TJ, TM,** TN, TR, TT, **TZ,** UA, **UG,** US, **UZ, VC, VN, ZA, ZM, ZW**

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available):* ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, **DK,** EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, **BJ,** CF, CG, CI, CM, GA, GN, GQ, GW, ML, **MR,** NE, SN, TD, TG).

Declaration under Rule 4.17:
— *as to the identity of the inventor (Rule 4.17(i))*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
9 October 2008

(54) Title: COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES

(57) Abstract: A composition for treating, reducing, ameliorating, or alleviating a back-of-the- eye condition or disorder that has an etiology in inflammation comprises a dissociated glucocorticoid receptor agonist ("DIGRA"). The compositions also can include other anti-inflamatory agents, anti-angiogenic agents, or combinations thereof. The composition can be formulated for topical application, injection, or implantation. The composition can be administered alone or in combination with another procedure chosen to enhance the outcome of the treatment.

WO 2008/021729 A3

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2007/074943

A. CLASSIFICATION OF SUBJECT MATTER
INV.. A61K31/343 A61K31/404 A61K31/4184 A61K31/4439 A61K31/4709
A61K31/4725 A61K31/395 A61K45/06 A61P27/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K A61P-

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal , EMBASE, CHEM ABS Data, BIOSIS, WPI Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO **BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	WO 2006/050998 A (SCHERING AG [DE]; JAROCH STEFAN [DE]; REHWINKEL HARTMUT [DE]; SCHAECKE) 18 May 2006 (2006-05-18) cited in the application page 1, 1ine 19 - line 21 page 5, 1ine 23 - line 28 page 14, line 3 - line 8 page 16, line 29 - page 17, line 3 page 19, line 5 - page 20, line 6	1-15, 41-43, 45-54, 74-82 16,33., 34, 36-38, 44,55, 71-73

-/--

[X] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E[1]" earlier document but published on or after the international filing date

[1]L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

[1]P- document published prior to the International filing date but later than the priority date claimed

"T[1] later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

[1]X[1] document of particular relevance; the claimed invention cannot *be* considered novel or cannot be considered to involve an inventive step when the document is taken alone

[1]Y" document of particular relevance; the claimed Invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu¬ments, such combination being obvious to a person skilled in the art.

[1]&" document member of the same patent family

Date of the actual completion of the International search	Date of mailing of the International search report
13 June 2008	01/08/2008
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Gradassi , Giulia

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2007/074943

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2004/005229 A (PFIZER PROD INC [US] ; CHANTIGNY YVES ANDRE [US] ; KLEINMAN EDWARD FOX [ ) 15 January 2004 (2004-01-15) page 28, line 1 - line 6 page 28, line 35 - page 33, line 36 page 34, line 19 - page 35, line 16	1-4,41 , 74-76
X	WO 2004/110385 A (SQUIBB BRISTOL MYERS CO [US] ; HADIDA-RUAH SARA SABINE [US] ; HE XIAOHUI) 23 December 2004 (2004-12-23) page 8 , line 7 - page 9 , line 31 page 15, line 4 - page 18,. line 8 page 31, line 30 - page 33, line 10	1-4,41 , 74-76
Y	MICHEL SHAWKAT SHAFIK ET AL: "Multifocal choroiditi s and panuveiti s: immunomodul atory therapy. " OPHTHALMOLOGY FEB 2002, . vol . 109, no. 2, February 2002 (2002-02) , pages 378-383, XP002483909 ISSN: 0161-6420 page 378, right-hand col umn, paragraph 4 - page 379, right-hand col umn , paragraph 1 page 380, left-hand column, paragraph 1 - page 381 , right-hand col umn , paragraph 2	16, 33, 34 , 36-38, 44,55
Y	JAMPOL L M ET AL: "Treatment of , juxtafoveal and extrafoveal choroidal neovascul arizati on i n the era of photody ńami c therapy with verteporfin" AMERICAN JOURNAL OF OPHTHALMOLOGY 2002 US, vol . 134, no. 1, 2002, pages 99-101 , XP002483910 ISSN: 0002-9394 the whole document	71-73
Y	TENNANT M T ET AL: "Photodynamic Therapy (PDT) i n Multifocal Choroiditi s (MFC) . " ARVO ANNUAL MEETING ABSTRACT SEARCH AND PROGRAM PLANNER, vol . 2002, 2002, page Abstract No. 595, XP008092817 & ANNUAL MEETING OF THE ASSOCIATION FOR RESEARCH I N VISION AND OPHTHALMOLOGY; FORT LAUDERDALE , FLORIDA, USA; MAY 05-10, 2002 the whole document	71-73
Y	US 6 316 465 Bl (PERSHADSINGH HARRIHAR A [US] ET AL) 13 November 2001 (2001-11-13) cited i n the appl ication col umn 9, line 32 - column 10, line 67 column 18, line 66 - column 19, line 13 table 1 cl aims 1,8	16,33, 34, 36-38, 44,55

-/--

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2007/074943

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2004/121014 A1 (GUO HONG [US] ET AL) 24 June 2004 (2004-06-24) the whole document	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2007/074943

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 41-55 and 71-73 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition,.

2. [ ] Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additi onal sheet

1. [ ] As all required additional search fees were timely paid by the applicant, this international search report covers allsearchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this international search reportcovers only those claims for which fees were paid, specifically claims Nos.:

4. [X] No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

see annex

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of **a** protest fee.

[ ] The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified In the invitation.

[ ] No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-15 (partially), 16 (totally), 33-34 (partially), 36-38 (partially), 41-54 (partially), 55 (totally), 71-82 (partially)

The composition of claim 6 comprising an anti-inflammatory agent and wherein the DIGRA of Formula (I) comprises A and Q which are independently selected from the group consisting of aryl and heteroaryl groups substituted with at least a halogen atom, cyano group, hydroxy group, or Cl-ClO alkoxy group; Rl, R2 and R3 independently selected from the group consisting of unsubstituted and substituted C1-C5 alky! groups; B is a C1-C5 alkylene group; D is the -NH or -NR' group, wherein R' is a C1-C5 alkyl group; and E is the hydroxy group.

---

2. claims: 1-9 (partially), 11 (partially), 33-34 (partially), 41-48 (partially), 50 (partially), 55 (partially), 71-72 (partially), 74-77 (partially), 79 (partially)

The composition of claim 6 comprising an anti-inflammatory agent and wherein the DIGRA has Formula (I) of claim 11, in which* notably R3 comprises a completely halogenated Cl-ClO alkyl group, and wherein all the compounds of the formula overlapping with earlier defined invention 1 are considered to pertain to this earlier defined invention 1.

---

3. claims: 1-9 (partially), 17 (partially), 33-34 (partially), 41-48 (partially), 56 (partially), 71-72 (partially), 74-77 (partially)

The composition of claim 6 comprising an anti-inflammatory agent and wherein the DIGRA has Formula (I) of claim 17 and wherein any embodiment falling within this definition and also pertai.ning to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

4. claims: 1-9 (partially), 18 (partially), 33-34 (partially), 41-48 (partially), 57 (partially), 71-72 (partially), 74-77 (partially)

FURTHER INFORKIATION CONTINUED FROM PCT/ISA/ 210

The composition of claim 6 comprising an anti-inflammatory agent and wherein the DISRA has Formula (I) of claim 18 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

5. claims: 1-9 (partially), 19 (partially), 33-34 (partially), 41-48 (partially), 58 (partially), 71-72 (partially), 74-77 (partially).

The composition of claim 6 comprising an anti-inflammatory agent and wherein the DIGRA has Formula (I) of claim 19 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

6. claims: 1-9 (partially), 20 (partially), 33-34 (partially), 41-48 (partially), 59 (partially), 71-72 (partially), 74-77 (partially)

The composition of claim 6 comprising an anti-inflammatory agent and wherein the DIGRA has Formula (I) of claim 20 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

7. claims: 1-9 (partially), 21 (partially), 33-34 (partially), 41-48 (partially), 60 (partially), 71-72 (partially), 74-77 (partially)

The composition of claim 6 comprising an anti-inflammatory agent and wherein the DIGRA has Formula (I) of claim 21 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

8. claims: 1-9 (partially), 22 (partially), 33-34 (partially), 41-48 (partially), 61 (partially), 71-72 (partially), 74-77 (partially)

FURTHER INFORMATION CONTINUED FROM PCTΛSA/ 210

The composition of claim 6 comprising an anti-inflammatory agent and wherein the DIGRA has Formula (I) of claim 22 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

9. claims: 1-9 (partially), 23 (partially), 33-34 (partially), 41-48 (partially), 62 (partially), 71-72 (partially), 74-77 (partially)

The composition of claim 6 comprising an anti-inflammatory agent and wherein the DIGRA has Formula (I) of claim 23 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it .pertains.

---

10. claims: 1-9 (partially), 24 (partially), 33-34 (partially), 41-48 (partially), 63 (partial ly), 71-72 (partially), 74-77 (partially)

The composition of claim 6 comprising an anti-inflammatory agent and wherein the DIGRA has Formula (I) of claim 24 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

11. claims: 1-9 (partially), 25 (partially), 33-34 (partially), 41-48 (partially), 64 (partially), 71-72 (partially), 74-77 (partially)

The composition of claim 6 comprising an anti-inflammatory agent and wherein the DIGRA has Formula (I) of claim 25 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

12. claims: 1-9 (partially), 26 (partially), 33-34 (partially), 41-48 (partially), 65 (partially), 71-72 (partially), 74-77 (partially)

FURTHER INFORMATION COMTINUED FROM PCT/ISA/ 210

The composition of claim 6 comprising an anti-inflammatory agent and wherein the DIGRA has Formula (I) of claim 26 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

13. claims: 1-9 (partially), 27 (partially), 33-34 (partially), 41-48 (partially), 66 (partially), 71-72 (partially), 74-77 (partially)

The composition of claim 6 comprising an anti-inflammatory agent and wherein the DIGRA has Formula (I) of claim 27 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

14. claims: 1-9 (partially), 28 (partially), 33-34 (partially), 41-48 (partially), 67 (partially), 71-72 (partially), 74-77 (partially)

The composition of claim 6 comprising an anti-inflammatory agent and wherein the DIGRA has Formula (I) of claim 28 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

15. claims: 1-9 (partially), 29 (partially), 33-34 (partially), 41-48 (partially), 68 (partially), 71-72 (partially), 74-77 (partially)

The composition of claim 6 comprising an anti-inflammatory agent and wherein the DIGRA has Formula (I) of claim 29 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

16. claims: 1-9 (partially), 30 (partially), 33-34 (partially), 41-48 (partially), 69 (partially), 71-72 (partially), 74-77 (partially)

FURTHER INFORMATION CONTINUED FROWI PCT/ISA/ 210

The composition of claim 6 comprising an anti-inflammatory agent and wherein the DIGRA has Formula (I) of claim 30 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

17. claims: 1-9 (partially), 31 (partially), 33-34 (partially), 41-48 (partially), 70 (partially), 71-72 (partially), 74-77 (partially)

The composition of claim 6 comprising an anti-inflammatory agent and wherein the DIGRA has Formula (I) of claim 31 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

18. claims: 1-9 (partially), 32 (partia.lly), 33-34 (partially), 41-48 (partially), 71-72 (partially), 74-77 (partially)

The composition of claim 6 comprising an anti-inflammatory agent and wherein the DIGRA has Formula (I) of claim 32 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

19. claims: 1-15 (partially), 33-38 (partially), 39-40 (totally), 41-54(partially), 71-82 (partially)

The composition of claim 6 comprising an anti-angiogenic agent and wherein the DIGRA of Formula (I) comprises A and Q which are independently selected from the group consisting of aryl and heteroaryl groups substituted with at least a halogen atom, cyano group, hydroxy group, or Cl-ClO alkoxy group; Rl, R2 and R3 independently selected from the group consisting of unsubstituted and substituted C1-C5 alkyl groups; B is a C1-C5 alkylene group; D is the -NH or -NR' group, wherein R' is a C1-C5 alkyl group; and E is the hydroxy group; and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

20. claims: 1-9 (partially), 11 (partially), 33-35 (partially),

FURTHER INFORMATION CONTINUED FROM PCTΛSA/ 210

41-48 (parti al ly) , 50 (parti al ly) , 55 (partial ly) , 71-72 (parti al ly) , 74-77 (parti al ly) , 79 (parti al ly)

The composition of cl aim 6 compri sing an anti-infl ammatory agent and wherein the DIGRA has Formul a (I) of cl aim 11, i n which notably R3 comprises a completely halogenated Cl-ClO al kyl group, and wherei n any embodiment overl appi ng with earl ier defined invention(s) i s considered t o pertain t o the first defi ned i nvention t o which i t pertains .

---

21. cl aims: 1-9 (parti al ly) , 17 (parti al ly) , 33-35 (parti al ly) , 41-48 (parti al ly) , 56 (parti al ly) , 71-72 (parti al ly) , 74-77 (parti al ly)

The composition of claim 6 compri sing an anti -angiogenic agent and wherein the DIGRA has Formul a (I) of cl aim 17 and wherei n any embodiment fal l ing within thi s defi nition and al so pertaining t o earl ier defined invention(s) , i s considered t o fal l within the first defined inventi on t o which i t pertai ns.

---

22. cl aims: 1-9 (parti al ly) , 18 (parti al ly) , 33-35 (parti al ly) , 41-48 (parti al ly) , 57 (partial ly) , 71-72 (parti al ly) , 74-77 (parti al ly)

The compositi on of cl aim 6 compri sing an anti-angiogenic agent and wherein the DIGRA has Formul a (I) of cl aim 18 and wherein any embodiment fal l ing within thi s definiti on and al so pertaining t o earl ier defined inventi ón(s) , i s considered t o fal l withi n the first defined invention t o which i t pertai ns.

---

23. cl aims: 1-9 (parti al ly) , 19 (parti al ly) , 33-35 (parti al ly) , 41-48 (parti al ly) , 58 (parti al ly) , 71-72 (partial ly) , 74-77 (parti al ly)

The composition of cl aim 6 compri sing an anti-angiogenic agent and wherei n the DIGRA has Formul a (I) of cl aim 19 and wherein any embodiment fal l ing within thi s definition and al so pertaining t o earl ier defined invention(s) , i s considered t o fal l within the first defined invention t o which i t pertains .

---

24. cl aims: 1-9 (parti al ly) , 20 (parti al ly) , 33-35 (parti al ly) ,

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

41-48 (partially), 59 (partially), 71-72 (partially), 74-77 (partially)

The composition of claim 6 comprising an anti-angiogenic agent and wherein the DIGRA has Formula (I) of claim 20 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains..

---

25. claims: 1-9 (partially), 21 (partially), 33-35 (partially), 41-48 (partially), 60 (partially), 71-72 (partially), 74-77 (partially)

The composition of claim 6 comprising an anti-angiogenic agent and wherein the DIGRA has Formula (I) of claim 21 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains .

---

26. claims: 1-9 (partially), 22 (partially), 33-35 (partially), 41-48 (partially), 61 (partially), 71-72 (partially), 74-77 (partially)

The composition of claim 6 comprising an anti-angiogenic agent and wherein the DIGRA has Formula (I) of claim 22 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains .

---

27. claims: 1-9 (partially), 23 (partially), 33-35 (partially), 41-48 (partially), 62 (partially), 71-72 (partially), 74-77 (partially)

The composition of claim 6 comprising an anti-angiogenic agent and wherein the DIGRA has Formula (I) of claim 23 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains .

---

28. claims: 1-9 (partially), 24 (partially), 33-35 (partially), 41-48 (partially), 63 (partially), 71-72 (partially), 74-77 (partially)

The composition of claim 6 comprising an anti-angiogenic agent and wherein the DIGRA has Formula (I) of claim 24 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

29. claims: 1-9 (partially), 25 (partially), 33-35 (partially), 41-48 (partially), 64 (partially), 71-72 (partially), 74-77 (partially)

The composition of claim 6 comprising an anti-angiogenic agent and wherein the DIGRA has Formula (I) of claim 25 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

30. claims: 1-9 (partially), 26 (partially), 33-35 (partially), 41-48 (partially), 65 (partially), 71-72 (partially), 74-77 (partially)

The composition of claim 6 comprising an anti-angiogenic agent and wherein the DIGRA has Formula (I) of claim 26 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

31. claims: 1-9 (partially), 27 (partially), 33-35 (partially), 41-48 (partially), 66 (partially), 71-72 (partially), 74-77 (partially)

The composition of claim 6 comprising an anti-angiogenic agent and wherein the DIGRA has Formula (I) of claim 27 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

32. claims: 1-9 (partially), 28 (partially), 33-35 (partially), 41-48 (partially), 67 (partially), 71-72 (partially), 74-77 (partially)

FURTHER INFORMATION CONTINUED FROM PCTΛSA/ 210

The composition of claim 6 comprising an anti-angiogenic agent and wherein the DIGRA has Formula (I) of claim 28 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

33. claims: 1-9 (partially), 29 (partially), 33-35 (partially), 41-48 (partially), 68 (partially), 71-72 (partially), 74-77 (partially)

The composition of claim 6 comprising an anti-angiogenic agent and wherein the DIGRA has Formula (I) of claim 29 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

34. claims: 1-9 (partially), 30 (partially), 33-35 (partially), 41-48 (partially), 69 (partially), 71-72 (partially), 74-77 (partially)

The composition of claim 6 comprising an anti-angiogenic agent and wherein the DIGRA has Formula (I) of claim 30 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

35. claims: 1-9 (partially), 31 (partially), 33-35 (partially), 41-48 (partially), 70 (partially), 71-72 (partially), 74-77 (partially)

The composition of claim 6 comprising an anti-angiogenic agent and wherein the DIGRA has Formula (I) of claim 31 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

---

36. claims: 1-9 (partially), 32 (partially), 33-35 (partially), 41-48 (partially), 71-72 (partially), 74-77 (partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

The composition of claim 6 comprising an anti-angiogenic agent and wherein the DIGRA has Formula (I) of claim 32 and wherein any embodiment falling within this definition and also pertaining to earlier defined invention(s), is considered to fall within the first defined invention to which it pertains.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US2007/074943

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2006050998 A	18-05-2006	AR 051767 A1	07-02-2007
		AU 2005303926 A1	18-05-2006
		CA 2586689 A1	18-05-2006
		EP 1844039 A1	17-10-2007
		JP 2008519803 T	12-06-2008
		KR 20070084192 A	24-08-2007
		UY 29213 A1	31-05-2006
WO 2004005229 A	15-01-2004	AU 2003281355 A1	23-01-2004
		BR 0312575 A	03-05-2005
		CA 2491994 A1	15-01-2004
		EP 1521733 A1	13-04-2005
		JP 2005532389 T	27-10-2005
		MX PA05000345 A	31-03-2005
		UY 27884 A1	27-02-2004
WO 2004110385 A	23-12-2004	NONE	
US 6316465 B1	13-11-2001	NONE	
US 2004121014 A1	24-06-2004	US 2007098760 A1	03-05--2007